Alcami to manufacture PharmaTher’s proprietary ketamine products
The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances
Three weeks after Alcami announced it was investing an additional $31 million to expand its sterile CDMO operation in Charleston, SC to increase its fill-finish and lyophilisation capacity, the company has agreed to manufacture PharmaTher's proprietary ketamine products.
PharmaTher, a clinical-stage psychedelics biotech company, is building a specialty ketamine-based product pipeline to support its internal product pipeline.
Alcami will support PharmaTher’s global ketamine product development and commercialisation plans by supplying expertise in GMP sterile fill-finish manufacturing and controlled substances.
The ability to manufacture and supply ketamine products in different dosage forms enables PharmaTher to guarantee delivery on its product pipeline as well as form partnerships with research labs, ketamine clinics and pharmaceutical companies that are seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and commercialise specific ketamine products for new indications.
PharmaTher’s proprietary ketamine drug products are expected to be available for FDA Phase III clinical studies and commercial use during the latter half of 2022.
Related News
-
News China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China
China is the pharma industry’s biggest gainer in the 2021 CPhI Annual Rankings, with digital matchmaking driving new waves of partnerships -
News UPDATED: COVID-19 Pharma Development Tracker
The latest coronavirus updates and developments impacting the global pharmaceutical supply chain -
News CBM secures funding from SK for C&G manufacturing expansion
SK's financial backing enables CBM to address significant capacity constraints in the cell and gene therapy manufacturing space -
News Lonza Switzerland site to undergo expansion of microbial development capabilities
The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects -
News Almac to employ 1,800 people in global recruitment drive
The CDMO will raise its headcount to 8,000 across its 19 global facilities amid increased demand for services -
News Hoth Therapeutics and WuXi strike API and drug product deal for cancer therapeutic
WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide -
News Meiji Seika to expand CDMO business with new manufacturing facility in India
The $20.1 million investment will enable the company to manufacture pharma products for the Adcock Ingram Group and for other clients -
News PCI Pharma Services to build Clinical Supply Centre of Excellence in New England
The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance